Not at all absurd for GBM. They already have the familiarity built in at many sites throughout the US, Canada, UK and Germany. Tight knit group of neuro oncologists and treating hospitals. The U.K. has immediate funding available to patients and Canada has a reciprocal agreement in place with the U.K. for approved treatments. Kristyn Powers is the NWBO rep needed for Canada so set up is through her. Dr. Bosch I believe has his residence not far from Germany so that angle is or will be covered when needed. There will he demand that comes quickly from off label self payers even perhaps before being determined to be SOC. Best wishes.
The phase 3 trial in effect was also a trial of the entities and steps and distribution of treating over 300 patients in four countries.
The actual administration of the vaccine is easy, like a flu shot as long as the low temperature facilities are available as they were for the trial.
The tumor is obtained by the neurosurgeon and frozen just as in the trial. The tumor is shipped to Sawston (or another certified facility such as CRL in Memphis if re-engaged) and the most sensitive part of the process is where is the leukapheresis(sp?) performed? Les implied that might be best done closer to the production facility due to timing/aging of dendritic cells maturation.
So for GBM it is plausible for nwbo to go it alone imo.
Market Data 
Markets 
AI
